AVAX Technologies, Inc. (AVXT) Research

AVAX Technologies, Inc. is an emerging biopharmaceutical company focused on pioneering autologous cell vaccine methods for cancer therapy. Its pipeline includes lead candidates M-VAX, for melanoma, and O-VAX, targeting ovarian cancer, both of which have successfully concluded Phase II clinical trials. The firm is also developing LungVax, a potential treatment for non-small cell lung cancer. Established in 1990, the Philadelphia, Pennsylvania-based entity initially operated as Walden Laboratories, Inc. before adopting its current name, AVAX Technologies, Inc., in March 1996.

Market snapshot

Symbol
AVXT
Price
$0.00
Day change
0.00%
Market cap
$6.9K
P/E ratio
-0.00x
52-week range
0.000001-0.00001
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Braxia Scientific Corp. (BRAXF)
  • DNAPrint Genomics, Inc. (DNAG)
  • Item 9 Labs Corp. (INLB)
  • Interpharm Holdings, Inc. (IPAH)
  • Jack Nathan Medical Corp. (JNHMF)
  • LadRx Corporation (LADX)
  • Mobile Lads Corp. (MOBO)
  • Mera Pharmaceuticals, Inc. (MRPI)

Recent insider activity

  • SPANA CARL — A-Award (40000 shares) on 2004-01-01

Open AVAX Technologies, Inc. (AVXT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.